Cryptotanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin-Mediated Cyclin D1 Expression and Rb Phosphorylation

被引:84
作者
Chen, Wenxing [1 ,4 ]
Luo, Yan [1 ]
Liu, Lei [1 ]
Zhou, Hongyu [1 ]
Xu, Baoshan [1 ]
Han, Xiuzhen [1 ]
Shen, Tao [1 ]
Liu, Zhijun [3 ]
Lu, Yin [4 ]
Huang, Shile [1 ,2 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA
[3] Louisiana State Univ, Sch Renewable Nat Resources, Baton Rouge, LA 70803 USA
[4] Nanjing Univ Chinese Med, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
SALVIA-MILTIORRHIZA BUNGE; BINDING PARTNER; MTOR; PATHWAY; RAPTOR; GROWTH; FEEDBACK; COMPLEX; RICTOR; AKT;
D O I
10.1158/1940-6207.CAPR-10-0020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cryptotanshinone (CPT), a natural compound isolated from the plant Salvia miltiorrhiza Bunge, is a potential anticancer agent. However, little is known about its anticancer mechanism. Here, we show that CPT inhibited cancer cell proliferation by arresting cells in G(1)-G(0) phase of the cell cycle. This is associated with the inhibition of cyclin D1 expression and retinoblastoma (Rb) protein phosphorylation. Furthermore, we found that CPT inhibited the signaling pathway of the mammalian target of rapamycin (mTOR), a central regulator of cell proliferation. This is evidenced by the findings that CPT inhibited type I insulin-like growth factor 1- or 10% fetal bovine serum-stimulated phosphorylation of mTOR, p70 S6 kinase 1, and eukaryotic initiation factor 4E binding protein 1 in a concentration-and time-dependent manner. Expression of constitutively active mTOR conferred resistance to CPT inhibition of cyclin D1 expression and Rb phosphorylation, as well as cell growth. The results suggest that CPT is a novel antiproliferative agent. Cancer Prev Res; 3(8); 1015-25. (C) 2010 AACR.
引用
收藏
页码:1015 / 1025
页数:11
相关论文
共 56 条
[31]   Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control [J].
Loewith, R ;
Jacinto, E ;
Wullschleger, S ;
Lorberg, A ;
Crespo, JL ;
Bonenfant, D ;
Oppliger, W ;
Jenoe, P ;
Hall, MN .
MOLECULAR CELL, 2002, 10 (03) :457-468
[32]   Cell cycle, CDKs and cancer: a changing paradigm [J].
Malumbres, Marcos ;
Barbacid, Mariano .
NATURE REVIEWS CANCER, 2009, 9 (03) :153-166
[33]   Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells [J].
Nizamutdinova, Irina Tsoy ;
Lee, Gyeong Won ;
Son, Kun Ho ;
Jeon, Su Jin ;
Kang, Sam Sik ;
Kim, Yeong Shik ;
Lee, Jae Heun ;
Seo, Han Geuk ;
Chang, Ki Churl ;
Kim, Hye Jung .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (03) :485-491
[34]   INTERLEUKIN-2-MEDIATED ELIMINATION OF THE P27(KIP1) CYCLIN-DEPENDENT KINASE INHIBITOR PREVENTED BY RAPAMYCIN [J].
NOURSE, J ;
FIRPO, E ;
FLANAGAN, WM ;
COATS, S ;
POLYAK, K ;
LEE, MH ;
MASSAGUE, J ;
CRABTREE, GR ;
ROBERTS, JM .
NATURE, 1994, 372 (6506) :570-573
[35]   mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt [J].
O'Reilly, KE ;
Rojo, F ;
She, QB ;
Solit, D ;
Mills, GB ;
Smith, D ;
Lane, H ;
Hofmann, F ;
Hicklin, DJ ;
Ludwig, DL ;
Baselga, J ;
Rosen, N .
CANCER RESEARCH, 2006, 66 (03) :1500-1508
[36]   Pharmacokinetic characterization of hydroxylpropyl-β-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza) [J].
Pan, Y. ;
Bi, H. -C. ;
Zhong, G. -P. ;
Chen, X. ;
Zuo, Z. ;
Zhao, L. -Z. ;
Gu, L. -Q. ;
Liu, P. -Q. ;
Huang, Z. -Y. ;
Zhou, S. -F. ;
Huang, M. .
XENOBIOTICA, 2008, 38 (04) :382-398
[37]   Identification of Protor as a novel Rictor-binding component of mTOR complex-2 [J].
Pearce, Laura R. ;
Huang, Xu ;
Boudeau, Jerome ;
Pawlowski, Rafal ;
Wullschleger, Stephan ;
Deak, Maria ;
Ibrahim, Adel F. M. ;
Gourlay, Robert ;
Magnuson, Mark A. ;
Alessi, Dario R. .
BIOCHEMICAL JOURNAL, 2007, 405 (03) :513-522
[38]   E2F-at the crossroads of life and death [J].
Polager, Shirley ;
Ginsberg, Doron .
TRENDS IN CELL BIOLOGY, 2008, 18 (11) :528-535
[39]   PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase [J].
Sancak, Yasemin ;
Thoreen, Carson C. ;
Peterson, Timothy R. ;
Lindquist, Robert A. ;
Kang, Seong A. ;
Spooner, Eric ;
Carr, Steven A. ;
Sabatini, David M. .
MOLECULAR CELL, 2007, 25 (06) :903-915
[40]   Cyclins and CDKS in development and cancer: lessons from genetically modified mice [J].
Santamaria, D ;
Ortega, S .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :1164-1188